Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Nicotine Delivery Systems | 18 | 2024 | 193 | 7.300 |
Why?
|
| Tobacco Products | 18 | 2024 | 189 | 6.890 |
Why?
|
| Social Media | 9 | 2024 | 50 | 4.860 |
Why?
|
| Vaping | 11 | 2023 | 122 | 4.260 |
Why?
|
| Nicotine | 13 | 2024 | 82 | 3.400 |
Why?
|
| Sexual and Gender Minorities | 8 | 2025 | 38 | 3.320 |
Why?
|
| Substance-Related Disorders | 8 | 2024 | 177 | 3.070 |
Why?
|
| Cigarette Smoking | 5 | 2022 | 76 | 3.050 |
Why?
|
| Smoking Cessation | 9 | 2022 | 399 | 2.730 |
Why?
|
| Tobacco Use Disorder | 4 | 2022 | 115 | 1.920 |
Why?
|
| Adolescent | 21 | 2025 | 2996 | 1.910 |
Why?
|
| Tobacco Use | 8 | 2025 | 85 | 1.760 |
Why?
|
| Smoking | 7 | 2022 | 466 | 1.630 |
Why?
|
| Intention | 4 | 2023 | 76 | 1.580 |
Why?
|
| Smokers | 5 | 2022 | 123 | 1.580 |
Why?
|
| Young Adult | 17 | 2025 | 2636 | 1.550 |
Why?
|
| Humans | 53 | 2025 | 27175 | 1.500 |
Why?
|
| Male | 32 | 2025 | 13034 | 1.340 |
Why?
|
| Adult | 24 | 2025 | 7510 | 1.280 |
Why?
|
| Female | 32 | 2025 | 14658 | 1.260 |
Why?
|
| Cannabis | 2 | 2024 | 42 | 1.020 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 936 | 0.880 |
Why?
|
| Lung Injury | 1 | 2023 | 32 | 0.850 |
Why?
|
| Cotinine | 2 | 2019 | 45 | 0.780 |
Why?
|
| Binge Drinking | 1 | 2021 | 6 | 0.740 |
Why?
|
| Peer Group | 1 | 2021 | 36 | 0.720 |
Why?
|
| Health Equity | 1 | 2020 | 7 | 0.720 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 39 | 0.710 |
Why?
|
| Health Status Disparities | 1 | 2020 | 61 | 0.680 |
Why?
|
| Health Behavior | 2 | 2020 | 152 | 0.670 |
Why?
|
| Biomedical Research | 1 | 2020 | 93 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 365 | 0.650 |
Why?
|
| Research Design | 1 | 2020 | 173 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 89 | 0.640 |
Why?
|
| Homosexuality, Female | 1 | 2019 | 3 | 0.640 |
Why?
|
| Bisexuality | 1 | 2019 | 3 | 0.640 |
Why?
|
| Homosexuality, Male | 1 | 2019 | 16 | 0.630 |
Why?
|
| Behavior, Addictive | 1 | 2019 | 23 | 0.630 |
Why?
|
| Prevalence | 4 | 2022 | 475 | 0.620 |
Why?
|
| Health Promotion | 1 | 2020 | 171 | 0.620 |
Why?
|
| Marijuana Use | 1 | 2018 | 32 | 0.590 |
Why?
|
| Social Networking | 1 | 2017 | 5 | 0.580 |
Why?
|
| Blood Donors | 1 | 2017 | 4 | 0.570 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 67 | 0.570 |
Why?
|
| Pharmaceutical Preparations | 2 | 2023 | 44 | 0.560 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 64 | 0.550 |
Why?
|
| Social Support | 1 | 2017 | 123 | 0.540 |
Why?
|
| Self Efficacy | 1 | 2017 | 73 | 0.540 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 10 | 0.530 |
Why?
|
| Outpatients | 1 | 2016 | 44 | 0.520 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 43 | 0.520 |
Why?
|
| Pharmacists | 1 | 2016 | 69 | 0.500 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 932 | 0.500 |
Why?
|
| Health Maintenance Organizations | 3 | 2011 | 9 | 0.480 |
Why?
|
| San Francisco | 3 | 2019 | 8 | 0.480 |
Why?
|
| Self Report | 3 | 2020 | 116 | 0.470 |
Why?
|
| Kidney | 1 | 2016 | 275 | 0.470 |
Why?
|
| Tobacco | 3 | 2023 | 86 | 0.440 |
Why?
|
| Minority Groups | 3 | 2025 | 64 | 0.440 |
Why?
|
| Pandemics | 4 | 2021 | 176 | 0.420 |
Why?
|
| California | 3 | 2022 | 64 | 0.410 |
Why?
|
| Stress, Psychological | 2 | 2025 | 209 | 0.400 |
Why?
|
| United States | 6 | 2025 | 2063 | 0.390 |
Why?
|
| Cities | 2 | 2021 | 14 | 0.370 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 14 | 0.360 |
Why?
|
| Job Satisfaction | 1 | 2011 | 24 | 0.360 |
Why?
|
| Prospective Studies | 3 | 2024 | 1224 | 0.350 |
Why?
|
| Diazepam | 1 | 2010 | 3 | 0.350 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 7 | 0.350 |
Why?
|
| Primary Health Care | 1 | 2011 | 149 | 0.320 |
Why?
|
| Flavoring Agents | 4 | 2023 | 15 | 0.320 |
Why?
|
| Saliva | 2 | 2019 | 94 | 0.310 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 160 | 0.310 |
Why?
|
| Appetite Depressants | 2 | 2005 | 2 | 0.310 |
Why?
|
| Cyclobutanes | 2 | 2005 | 3 | 0.310 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 404 | 0.290 |
Why?
|
| Pilot Projects | 2 | 2020 | 398 | 0.290 |
Why?
|
| Menthol | 3 | 2023 | 18 | 0.280 |
Why?
|
| Sex Factors | 2 | 2018 | 451 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 108 | 0.240 |
Why?
|
| Weight Loss | 1 | 2005 | 72 | 0.230 |
Why?
|
| Urban Population | 1 | 2025 | 72 | 0.230 |
Why?
|
| Cognitive Dissonance | 1 | 2024 | 1 | 0.230 |
Why?
|
| Rural Population | 1 | 2025 | 98 | 0.220 |
Why?
|
| Hallucinogens | 1 | 2024 | 12 | 0.220 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2023 | 12 | 0.220 |
Why?
|
| Product Labeling | 1 | 2023 | 10 | 0.210 |
Why?
|
| Obesity | 3 | 2005 | 651 | 0.210 |
Why?
|
| Respiratory System | 1 | 2022 | 13 | 0.210 |
Why?
|
| Robotics | 1 | 2023 | 42 | 0.200 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 73 | 0.200 |
Why?
|
| Social Behavior | 2 | 2020 | 52 | 0.200 |
Why?
|
| Tobacco, Smokeless | 1 | 2022 | 43 | 0.190 |
Why?
|
| Feasibility Studies | 1 | 2022 | 191 | 0.190 |
Why?
|
| Policy | 1 | 2021 | 11 | 0.190 |
Why?
|
| Odds Ratio | 1 | 2022 | 231 | 0.190 |
Why?
|
| Attitude | 1 | 2021 | 42 | 0.180 |
Why?
|
| Counseling | 1 | 2021 | 52 | 0.180 |
Why?
|
| Search Engine | 1 | 2020 | 7 | 0.180 |
Why?
|
| Perception | 1 | 2021 | 85 | 0.180 |
Why?
|
| Risk-Taking | 1 | 2021 | 58 | 0.180 |
Why?
|
| Aged | 4 | 2021 | 5232 | 0.180 |
Why?
|
| Anxiety | 1 | 2021 | 137 | 0.180 |
Why?
|
| Taxes | 1 | 2020 | 12 | 0.170 |
Why?
|
| Sleep Hygiene | 1 | 2020 | 1 | 0.170 |
Why?
|
| Los Angeles | 1 | 2020 | 13 | 0.170 |
Why?
|
| Cercopithecus | 1 | 2020 | 2 | 0.170 |
Why?
|
| Growth and Development | 1 | 2020 | 7 | 0.170 |
Why?
|
| Health Risk Behaviors | 1 | 2020 | 7 | 0.170 |
Why?
|
| Allostasis | 1 | 2020 | 5 | 0.170 |
Why?
|
| Bradykinin | 1 | 2019 | 27 | 0.170 |
Why?
|
| Commerce | 1 | 2020 | 47 | 0.170 |
Why?
|
| Alcoholism | 1 | 2021 | 117 | 0.170 |
Why?
|
| Veins | 1 | 2019 | 19 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2020 | 58 | 0.170 |
Why?
|
| Afferent Pathways | 1 | 2019 | 62 | 0.170 |
Why?
|
| Colorado | 3 | 2011 | 47 | 0.170 |
Why?
|
| Pericardium | 1 | 2019 | 47 | 0.160 |
Why?
|
| Depression | 1 | 2021 | 211 | 0.160 |
Why?
|
| Social Environment | 1 | 2020 | 56 | 0.160 |
Why?
|
| Cohort Studies | 1 | 2022 | 864 | 0.160 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 79 | 0.160 |
Why?
|
| Sympathetic Nervous System | 1 | 2019 | 67 | 0.160 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2019 | 77 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 990 | 0.160 |
Why?
|
| Sexuality | 1 | 2019 | 4 | 0.160 |
Why?
|
| Reflex | 1 | 2019 | 74 | 0.160 |
Why?
|
| Gender Identity | 1 | 2019 | 21 | 0.160 |
Why?
|
| Transgender Persons | 1 | 2019 | 10 | 0.160 |
Why?
|
| Hemodynamics | 1 | 2019 | 220 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2020 | 184 | 0.150 |
Why?
|
| Friends | 1 | 2018 | 12 | 0.150 |
Why?
|
| Placebo Effect | 1 | 2018 | 6 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 762 | 0.150 |
Why?
|
| Diet | 1 | 2020 | 225 | 0.150 |
Why?
|
| Persuasive Communication | 1 | 2018 | 13 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2018 | 28 | 0.150 |
Why?
|
| Psychological Theory | 1 | 2018 | 29 | 0.150 |
Why?
|
| Family | 1 | 2018 | 98 | 0.140 |
Why?
|
| Models, Psychological | 1 | 2018 | 80 | 0.140 |
Why?
|
| Social Norms | 1 | 2017 | 11 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 448 | 0.140 |
Why?
|
| Mental Health | 3 | 2024 | 97 | 0.140 |
Why?
|
| Cues | 1 | 2017 | 39 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 162 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 4 | 0.130 |
Why?
|
| Contraindications | 1 | 2016 | 13 | 0.130 |
Why?
|
| Motivation | 1 | 2018 | 210 | 0.130 |
Why?
|
| Exercise | 1 | 2021 | 469 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 724 | 0.130 |
Why?
|
| Biomarkers | 1 | 2019 | 736 | 0.130 |
Why?
|
| Middle Aged | 4 | 2021 | 6918 | 0.120 |
Why?
|
| Child | 1 | 2021 | 2163 | 0.120 |
Why?
|
| Students | 1 | 2017 | 191 | 0.120 |
Why?
|
| Time Factors | 1 | 2018 | 1573 | 0.110 |
Why?
|
| Heterosexuality | 2 | 2024 | 17 | 0.100 |
Why?
|
| Organizational Culture | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 73 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 63 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2011 | 113 | 0.080 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2024 | 6 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 14 | 0.060 |
Why?
|
| Marketing | 1 | 2024 | 34 | 0.050 |
Why?
|
| Metformin | 1 | 2004 | 34 | 0.050 |
Why?
|
| Disease Management | 1 | 2004 | 86 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 78 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 43 | 0.050 |
Why?
|
| Smoke | 1 | 2023 | 33 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 58 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2019 | 351 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2004 | 307 | 0.050 |
Why?
|
| Body Composition | 1 | 2004 | 262 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 398 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 45 | 0.040 |
Why?
|
| Oklahoma | 1 | 2024 | 977 | 0.040 |
Why?
|
| Cercopithecidae | 1 | 2020 | 1 | 0.040 |
Why?
|
| C-Peptide | 1 | 2020 | 8 | 0.040 |
Why?
|
| Grooming | 1 | 2020 | 3 | 0.040 |
Why?
|
| Receptors, Bradykinin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2019 | 32 | 0.040 |
Why?
|
| Competitive Behavior | 1 | 2020 | 17 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 34 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 114 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 106 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 107 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2019 | 163 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 538 | 0.040 |
Why?
|
| Heart Rate | 1 | 2019 | 375 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 597 | 0.040 |
Why?
|
| Rats | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 10082 | 0.030 |
Why?
|
| Body Constitution | 1 | 2004 | 11 | 0.010 |
Why?
|
| Health Services Research | 1 | 2004 | 41 | 0.010 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2004 | 10 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 46 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 59 | 0.010 |
Why?
|
| Arginine | 1 | 2004 | 39 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 50 | 0.010 |
Why?
|
| Testosterone | 1 | 2004 | 68 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 246 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 405 | 0.010 |
Why?
|
| Lipids | 1 | 2004 | 199 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2004 | 172 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 291 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 324 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 2289 | 0.010 |
Why?
|